focusing on the development and commercialization of "High Barrier to Entry" generic drugs. TWi focuses primarily on the development of Paragraph IV and high technical barrier generic drugs requiring strong science and technical know-how, as well as under-serviced mature molecules to meet market needs. For more information about TWi Corporate and "High Barrier to Entry" generics, please click here to visit www.twipharma.com. Our goals are to expand our market presence in the United States as a strong industry partner, and to continue to identify, acquire, develop, license and launch technically challenging or mature molecule generic drugs.